Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

• to characterize the pharmacokinetic and the pharmacodynamic profile after intravenous bolus injection of unfractionated heparin (UFH) after repeated sc 100 IU anti-Xa/kg (corresponding to 1 mg/kg) twice a day during 2.5 days (every 12±2hrs) administrations of enoxaparin in Caucasian healthy subjects.

Secondary objective(s):

• to compare the pharmacokinetic and the pharmacodynamic profile between 3 different timing of administration of the UFH

• to assess the tolerability of the different anticoagulation protocols

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sanofi
• Treatments: Calcium heparin; Enoxaparin; Heparin

Criteria

Inclusion Criteria:

• Caucasian

• Male and female subjects, between 40 and 60 years of age

• Body weight between 50 kg and 90 kg if male and between 40 and 80 kg if female with Body Mass Index (BMI) between 18 and 29 kg/m2

Health Status:

• Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination)

• Subject with hypertension, hypo- or hyperthyroidism or dyslipidemia will be included if their concomitant pathology is well-controlled by treatment for at least one year

• Normal vital signs after 10 minutes resting in supine position:

• 95 mmHg < systolic blood pressure (SBP) < 140 mmHg;

• 45 mmHg < diastolic blood pressure (DBP) < 90 mmHg;

• 40 bpm < heart rate < 100 bpm.

• Normal 12-lead electrocardiogram (ECG); 120 ms < PR < 220 ms, QRS < 120 ms, QTc ≤ 430 ms for male, 450 ms for female or not considered as clinically significant by the investigator

• Laboratory parameters within the normal range unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; hepatic enzymes (aspartate amino-transferase or AST, alanine amino-transferase or ALT) should be strictly below the upper laboratory norm.

• Platelets ≥ 150 000 / mm3

• Mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) should be strictly in the normal range of the laboratory

• Activated partial thromboplastin time (aPTT) ratio should be comprised between 0.95 and 1.15

• Estimated Creatinine clearance by Cockroft formula should be higher than 50 mL/min

• Non smoker or smoking the equivalent or less than 5 cigarettes a day and able not to smoke during the study hospitalization

• Normal gynecological examination no longer than 12 months before inclusion.

• For female with childbearing potential using an effective contraception method (e.g. intra-uterine device, hormonal contraception, diaphragm and condom) except if postmenopausal for more than 12 months or sterilized for more than three months

• Subject with coagulation test and blood count (including platelets) within the physiological ranges)

Regulations:

• Having given written informed consent prior to any procedure related to the study

• Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research

• Not under any administrative or legal supervision

Exclusion Criteria:

Medical history and clinical status:

• Contra-indication to anticoagulant therapy

• Subject with known increased bleeding time, hemophilia, thrombocytopenia, and/or history of any vascular purpura

• Subject with detectable antibody against heparin in the blood

• Any history or presence of clinically relevant cardiovascular, gynecologic (for women), pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, ocular or infectious disease that is capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk factor when taking the study medication; any acute infectious disease or signs of acute illness; except subject with hypertension, hypo- or hyperthyroidism or dyslipidemia if well-controlled by treatment for at least one year.

• Subject with diabetes or other cardiovascular or metabolic disease

• Subject with INR > 1.5

• Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month)

• Blood donation or blood loss within one month before administration

• Symptomatic hypotension whatever the decrease in blood pressure or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position

• Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician

• History or presence of drug or alcohol abuse (alcohol consumption > 40 grams/day)

• Smoking more than 5 cigarettes or equivalent/day, or unable to stop smoking during the study

• Excessive consumption of beverages with xanthine bases (> 4 cups or glasses/day)

• Pregnancy (defined as positive beta-HCG plasma test that can not be explicated by menopauses), breast-feeding for female, any history or presence of clinically relevant gynecologic disease

Interfering substance:

• Any medication (including St John's Wort) within 14 days before administration, or within 5 times the elimination half-life of that drug, except for hormonal contraception or replacement therapy, and allowed therapy for stable pathology

• Anti-inflammatory treatments and anti-aggregant treatments are strictly forbidden during the whole study period

General conditions:

• Subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development

• Subject in exclusion period of a previous study according to applicable regulations

• Subject who cannot be contacted in case of emergency

• Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol or any other protocol of the Investigating Center

• Subject is an employee of the Investigating Center

Biological status:

• Positive reaction to any of the following tests: HBs antigen, anti-HCV antibodies, anti-HIV1 antibodies, anti-HIV2 antibodies, anti-LMWH antibodies

• Positive results on urine drug screen (amphetamines/metamphetamines, barbiturates, benzodiazepines, cannabinoids)

• Positive alcohol breath or plasma test